Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2

Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter
doi: https://doi.org/10.1101/2020.12.10.20235747
Wendy P. Painter
1Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: painter@ridgebackbio.com
Wayne Holman
1Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim A. Bush
2Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Firas Almazedi
2Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamzah Malik
2Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola C. J. E. Eraut
2Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merribeth J. Morin
1Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura J. Szewczyk
1Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George R. Painter
3Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 954 Gatewood Road NE, Atlanta, Georgia 30329, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: painter@ridgebackbio.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog ß-d-N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, seasonal and pandemic influenza viruses, and respiratory syncytial virus.

Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.

EIDD-1931 appeared rapidly in plasma, with a median time of maximum observed concentration of 1.00 to 1.75 hours, and declined with a geometric half-life of approximately 1 hour, with a slower elimination phase apparent following multiple doses or higher single doses (7.1 hours at the highest dose tested). Mean maximum observed concentration and area under the concentration versus time curve increased in a dose-proportional manner, and there was no accumulation following multiple doses. When administered in a fed state, there was a decrease in the rate of absorption, but no decrease in overall exposure.

Molnupiravir was well tolerated. Fewer than half of subjects reported an adverse event, the incidence of adverse events was higher following administration of placebo, and 93.3% of adverse events were mild. One discontinued early due to rash. There were no serious adverse events and there were no clinically significant findings in clinical laboratory, vital signs, or electrocardiography. Plasma exposures exceeded expected efficacious doses based on scaling from animal models; therefore, dose escalations were discontinued before a maximum tolerated dose was reached.

Clinical trial identifier This study was registered at ClinicalTrials.gov with the identifier NCT04392219.

Competing Interest Statement

Ridgeback Biotherapeutics LP funded this study and has subsequently entered into a collaboration with Merck to jointly develop molnupiravir. Wendy Painter is an employee of Ridgeback Biotherapeutics LP and previously was a consultant to Emory Institute of Drug Development; Merribeth Morin and Laura Szewczyk are employees of Ridgeback Biotherapeutics; Wayne Holman is a co founder, owner, and advisor to Ridgeback Biotherapeutics; Firas Almazedi, Hamzah Malik, and Nicola Eraut are employees of Covance Clinical Research Unit Limited (the drug development division of Laboratory Corporation of America Holdings), which was responsible for the clinical conduct of this study; Jim Bush is an employee of Covance Clinical Research Unit Limited and is an equity holder of Laboratory Corporation of America Holdings; George Painter is the director of the Emory Institute of Drug Development, is the chief executive officer of Drug Innovation Ventures at Emory, and has a financial interest in molnupiravir.

Clinical Trial

NCT04392219

Funding Statement

Ridgeback Biotherapeutics LP funded this study and has subsequently entered into a collaboration with Merck to jointly develop molnupiravir.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NHS Health Research Authority North East-York Research Ethics Committee, NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle Upon Tyne, UK

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Not yet published.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2
Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter
medRxiv 2020.12.10.20235747; doi: https://doi.org/10.1101/2020.12.10.20235747
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2
Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter
medRxiv 2020.12.10.20235747; doi: https://doi.org/10.1101/2020.12.10.20235747

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1771)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10816)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2961)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1934)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12528)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (88)
  • Nephrology (325)
  • Neurology (2811)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (599)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (339)
  • Psychiatry and Clinical Psychology (2649)
  • Public and Global Health (5384)
  • Radiology and Imaging (1018)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)